Search Here

Federal regulators have approved the speciality drug-maker Biogen Idec's new treatment for people with relapsing forms of multiple sclerosis. 

The company said in a statement that the Food and Drug Administration cleared the injectable drug, called Plegridy, after reviewing results from a study involving more than 1,500 people with the disease. 

Multiple sclerosis is a disease of the immune system in which the body attacks its own brain and spinal cord. The symptoms can come and go, often reappearing after every few month. 

Recently the drug Plegridy was also approved by European Commission. 

Biogen Idec also markets other multiple sclerosis drugs such as Avonex and Tysabri. 

Shares of Biogen Idec Inc. ended regular trading up $5.46, or 1.6 percent, to $342.47 on Friday, the press release added. Company's stock is up 22 percent this year.